CAPTRUST Financial Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $45.3M | Sell |
90,308
-3,765
| -4% | -$1.81M | 0.07% | 226 |
|
|
2026
Q1 | $46.2M | Buy |
94,073
+7,341
| +8% | +$3.98M | 0.08% | 208 |
|
|
2025
Q4 | $50.3M | Buy |
86,732
+1,025
| +1% | +$580K | 0.1% | 187 |
|
|
2025
Q3 | $41.6M | Sell |
85,707
-978
| -1% | -$455K | 0.08% | 201 |
|
|
2025
Q2 | $35.1M | Buy |
86,685
+969
| +1% | +$405K | 0.08% | 207 |
|
|
2025
Q1 | $42.7M | Buy |
85,716
+18,953
| +28% | +$10.3M | 0.11% | 174 |
|
|
2024
Q4 | $34.7M | Sell |
66,763
-683
| -1% | -$376K | 0.1% | 161 |
|
|
2024
Q3 | $41.7M | Sell |
67,446
-270
| -0.4% | -$160K | 0.12% | 145 |
|
|
2024
Q2 | $37.4M | Sell |
67,716
-1,632
| -2% | -$935K | 0.12% | 146 |
|
|
2024
Q1 | $40.3M | Sell |
69,348
-11,450
| -14% | -$6.43M | 0.15% | 135 |
|
|
2023
Q4 | $42.9M | Buy |
80,798
+348
| +0.4% | +$168K | 0.15% | 134 |
|
|
2023
Q3 | $40.7M | Buy |
80,450
+8,181
| +11% | +$4.36M | 0.16% | 130 |
|
|
2023
Q2 | $37.7M | Buy |
72,269
+1,862
| +3% | +$1M | 0.15% | 131 |
|
|
2023
Q1 | $40.6M | Buy |
70,407
+7,023
| +11% | +$3.96M | 0.18% | 122 |
|
|
2022
Q4 | $34.9M | Sell |
63,384
-271
| -0.4% | -$144K | 0.18% | 127 |
|
|
2022
Q3 | $32.3M | Buy |
63,655
+9,171
| +17% | +$5.13M | 0.19% | 116 |
|
|
2022
Q2 | $29.6M | Buy |
54,484
+4,950
| +10% | +$2.72M | 0.19% | 119 |
|
|
2022
Q1 | $29.3M | Buy |
49,534
+2,014
| +4% | +$1.16M | 0.19% | 126 |
|
|
2021
Q4 | $31.7M | Sell |
47,520
-1,234
| -3% | -$770K | 0.22% | 114 |
|
|
2021
Q3 | $27.9M | Sell |
48,754
-2,184
| -4% | -$1.2M | 0.23% | 112 |
|
|
2021
Q2 | $25.7M | Buy |
50,938
+240
| +0.5% | +$113K | 0.24% | 110 |
|
|
2021
Q1 | $23.1M | Buy |
50,698
+7,908
| +18% | +$3.77M | 0.25% | 105 |
|
|
2020
Q4 | $19.9M | Buy |
42,790
+3,714
| +10% | +$1.74M | 0.26% | 104 |
|
|
2020
Q3 | $17.1M | Sell |
39,076
-9,779
| -20% | -$4.04M | 0.28% | 96 |
|
|
2020
Q2 | $17.6M | Sell |
48,855
-7,858
| -14% | -$2.63M | 0.29% | 92 |
|
|
2020
Q1 | $15.6M | Buy |
56,713
+2,114
| +4% | +$667K | 0.34% | 76 |
|
|
2019
Q4 | $17.8M | Buy |
54,599
+15,939
| +41% | +$4.83M | 0.28% | 94 |
|
|
2019
Q3 | $11.3M | Sell |
38,660
-1,366
| -3% | -$391K | 0.4% | 57 |
|
|
2019
Q2 | $11.8M | Sell |
40,026
-874
| -2% | -$241K | 0.44% | 49 |
|
|
2019
Q1 | $11.2M | Sell |
40,900
-120
| -0.3% | -$29.9K | 0.45% | 44 |
|
|
2018
Q4 | $9.19M | Sell |
41,020
-266
| -0.6% | -$62.4K | 0.49% | 45 |
|
|
2018
Q3 | $10.1M | Sell |
41,286
-4,218
| -9% | -$970K | 0.45% | 40 |
|
|
2018
Q2 | $9.43M | Buy |
45,504
+5,368
| +13% | +$1.14M | 0.52% | 32 |
|
|
2018
Q1 | $8.16M | Sell |
40,136
-4,337
| -10% | -$910K | 0.5% | 33 |
|
|
2017
Q4 | $8.45M | Buy |
44,473
+44,390
| +53,482% | +$8.5M | 0.51% | 34 |
|
|
2017
Q3 | $17K | Buy |
+83
| New | +$15K | ﹤0.01% | 391 |
|
Other funds holding TMO
CAPTRUST Financial Advisors's TMO Position: Q2 2026 in Review
CAPTRUST Financial Advisors reduced its Thermo Fisher Scientific (TMO) stake by 4% in Q2 2026, selling an estimated $1.81M and leaving 90,308 shares worth $45.3M. The position accounts for 0.07% of the portfolio, ranked #226.
CAPTRUST Financial Advisors first reported a position in TMO in Q3 2017 and has held it in 36 quarters since. The position peaked at $50.3M in Q4 2025. 2,602 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- CAPTRUST Financial Advisors held 90,308 shares of Thermo Fisher Scientific worth $45.3M as of Q2 2026.
- CAPTRUST Financial Advisors sold 3,765 Thermo Fisher Scientific shares in Q2 2026, an estimated $1.81M.
- Thermo Fisher Scientific made up 0.07% of CAPTRUST Financial Advisors's portfolio in Q2 2026, its #226 holding.
- CAPTRUST Financial Advisors first reported a position in Thermo Fisher Scientific in Q3 2017 and has held it in 36 quarters since.
- CAPTRUST Financial Advisors's Thermo Fisher Scientific position peaked at $50.3M in Q4 2025.
- 2,602 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on CAPTRUST Financial Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.